Integrum AB's OPRA™ Implant System Shows Exceptional Outcomes
MÖLNDAL, Sweden — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) recently highlighted the impressive results of its OPRA™ Implant System following a two-year independent study conducted by the Walter Reed National Military Medical Center. This groundbreaking research provides strong evidence supporting the effectiveness of the implant system specifically for transfemoral amputees. The findings reveal substantial enhancements over traditional socket prostheses, offering a clear validation of Integrum's innovative technology and its clinical benefits for patients post-amputation.
Significant Improvements Documented in the Study
The study, classified as Level II Evidence, evaluates the most advanced version of the OPRA™ Implant System, which was first introduced in 2017. The remarkable outcomes recorded in this study emphasize numerous advantages for patients utilizing the implant, including heightened prosthetic usage, better mobility, and a marked increase in quality of life. Importantly, the results indicate superior performance in terms of fewer infections and complications, achieving a staggering 100% implant survival rate.
Comments from Integrum's Leadership
Scott Flora, the acting CEO of Integrum, expressed pride in the findings, stating, "This study confirms the safety, durability, and positive impact of the OPRA Implant System for individuals who have undergone amputation. We are honored to support the men and women who have served their country and are excited to see growing evidence supporting its role in improving mobility and overall well-being for amputees globally." These insights could drive further adoption of the innovative technology among healthcare providers and elevate awareness of the OPRA™ system among health professionals and prospective patients.
The Call for More Comprehensive Clinical Trials
Dr. Jonathan Forsberg, MD, PhD, currently associated with Memorial Sloan Kettering and a retired military member, emphasized the necessity for high-quality prospective clinical trials to validate the benefits of transdermal bone-anchored implants. He stated, "By further proving the safety and effectiveness of the OPRA Implant System, we hope this growing body of evidence will encourage exponential acceptance among US insurance providers for reimbursement, making this life-changing technology more accessible to patients in need."
Expert Opinions on the Findings
Dr. Benjamin K. Potter, MD, Chair of the Department of Orthopaedic Surgery at Penn Medicine, also conveyed his enthusiasm about the research results, stating, "We were excited to see that our results further confirmed the benefits of direct skeletal attachment for improving function and quality of life for patients with limb loss, while maintaining better than expected infection and major complication rates." His impressive military background adds depth to his insights into the study's findings.
Further Insights and Study Conclusion
The research was co-authored by a team of esteemed professionals, including Benjamin K. Potter, MD, Jonathan A. Forsberg, MD, PhD, LCDR Ashley B. Anderson, MD, Jason M. Souza, MD, and Julio Rivera, PhD. Their work was recently published in the Clinical Orthopaedics and Related Research journal, showcasing a significant step forward in prosthetic surgical practices.
Frequently Asked Questions
What is the OPRA™ Implant System?
The OPRA™ Implant System is a transdermal bone-anchored implant designed for transfemoral amputees to enhance mobility and quality of life.
How did the study measure the effectiveness of the OPRA™ system?
The study assessed the functional improvements and complications in transfemoral amputees using the OPRA™ system, compared to traditional prostheses.
Who are the experts involved in the study?
The study includes contributions from renowned professionals in orthopaedics and medicine, such as Dr. Benjamin K. Potter and Dr. Jonathan A. Forsberg.
What are the main findings of the study?
The study found significant benefits in mobility, reduced infections, and a 100% implant survival rate among users of the OPRA™ Implant System.
How can the findings impact the future use of the OPRA™ system?
The findings aim to foster greater adoption and acceptance of the OPRA™ system among healthcare providers and insurance companies, ultimately benefiting amputees in need.
